Larimar Therapeutics Appoints New CEO, Board Member
Ticker: LRMR · Form: 8-K · Filed: Jan 27, 2025 · CIK: 1374690
| Field | Detail |
|---|---|
| Company | Larimar Therapeutics, Inc. (LRMR) |
| Form Type | 8-K |
| Filed Date | Jan 27, 2025 |
| Risk Level | medium |
| Pages | 2 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: leadership-change, executive-appointment, board-of-directors
Related Tickers: LRMR
TL;DR
Larimar gets a new permanent CEO, Brian Markison, and Chairman of the Board. CMO changes too.
AI Summary
Larimar Therapeutics, Inc. announced on January 22, 2025, the appointment of Brian R. Markison as Chief Executive Officer and a member of the Board of Directors, effective immediately. Markison, previously the interim CEO, will also serve as Chairman of the Board. The company also announced the appointment of Dr. Paul L. Williams as Chief Medical Officer and the departure of Dr. Donald L. Staiger as Chief Medical Officer.
Why It Matters
The appointment of a permanent CEO and a new Chairman of the Board signifies a strategic shift and leadership stability for Larimar Therapeutics, potentially impacting its future direction and investor confidence.
Risk Assessment
Risk Level: medium — Leadership changes, especially the appointment of a new CEO and Chairman, can introduce uncertainty and signal strategic shifts, impacting the company's future performance and stock price.
Key Players & Entities
- Larimar Therapeutics, Inc. (company) — Registrant
- Brian R. Markison (person) — Appointed Chief Executive Officer and Chairman of the Board
- Dr. Paul L. Williams (person) — Appointed Chief Medical Officer
- Dr. Donald L. Staiger (person) — Departed Chief Medical Officer
- January 22, 2025 (date) — Effective date of appointments and departure
FAQ
Who has been appointed as the new Chief Executive Officer of Larimar Therapeutics?
Brian R. Markison has been appointed as the new Chief Executive Officer of Larimar Therapeutics.
What is Brian R. Markison's new role on the Board of Directors?
Brian R. Markison has been appointed as a member of the Board of Directors and will serve as Chairman of the Board.
Who has been appointed as the new Chief Medical Officer?
Dr. Paul L. Williams has been appointed as the new Chief Medical Officer.
Who has departed from the role of Chief Medical Officer?
Dr. Donald L. Staiger has departed from the role of Chief Medical Officer.
What is the effective date for these leadership changes?
The leadership changes are effective as of January 22, 2025.
Filing Stats: 645 words · 3 min read · ~2 pages · Grade level 11.1 · Accepted 2025-01-27 16:11:26
Key Financial Figures
- $0.001 — ch registered Common Stock, par value $0.001 per share LRMR Nasdaq Global Market
Filing Documents
- lrmr-20250122.htm (8-K) — 45KB
- lrmr-ex10_1.htm (EX-10.1) — 57KB
- 0000950170-25-009196.txt ( ) — 218KB
- lrmr-20250122.xsd (EX-101.SCH) — 23KB
- lrmr-20250122_htm.xml (XML) — 4KB
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits Below is a list of exhibits included with this Current Report on Form 8-K. Exhibit No. Document 10.1 Form of Performance-Based Restricted Stock Unit Award Agreement under the Larimar Therapeutics, Inc. 2020 Equity Incentive Plan* 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) * Filed herewith
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Larimar Therapeutics, Inc. Date: January 27, 2025 By: /s/ Carole S. Ben-Maimon, M.D. Name: Carole S. Ben-Maimon, M.D. Title: President and Chief Executive Officer